Stella Chang

Life Science Research

Stella Chang

Stella Chang is Vice President of Life Sciences Solutions at Veradigm, where she oversees a portfolio of EHR-sourced real world data (Veradigm Health Insights), clinical registries (PINNACLE, Diabetes Collaborative Registry), SaaS solutions (Evalytica), and point-of-care research (Veradigm Study Source) solutions.

AREA OF EXPERTISE

Real World Data / Evidence Health Economics and Outcomes Research Government Health Data Analytics and Policy

Stella Chang is Vice President of Life Sciences Solutions at Veradigm, where she oversees a portfolio of EHR-sourced real world data (Veradigm Health Insights), clinical registries (PINNACLE, Diabetes Collaborative Registry), SaaS solutions (Evalytica), and point-of-care research (Veradigm Study Source) solutions.

Prior to joining Veradigm in 2018, she led the design and delivery of products and services related to real world evidence and data analytics across the healthcare industry, including overseeing the MarketScan data and analytic platforms at Truven Health Analytics and supporting Federal healthcare initiatives for CMS, AHRQ and state All Payer Claims Databases (APCDs). Ms. Chang was formerly a health outcomes researcher with focus on cancer, diabetes and behavioral health. Ms. Chang has a bachelor’s degree in biology from Johns Hopkins University and a master’s degree in public health from Yale University.


References to published articles by this expert

  • Bonafede MM, Lenhart GM, Chang S. Patient survival following malignant brain tumor resection using a linked claims database. Value in Health. 2013;16(3):A130-1.
  • Katz M, Scherger J, Conrad S, Montejano L, Chang S. Healthcare costs associated with switching from brand to generic levothyroxine. American Health & Drug Benefits. 2010;3(2):127-34.
  • Wynn ML, Chang S, Peipins L. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. Journal of Women’s Health. 2007;16(7):971-86.
  • Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. Journal of Neurooncology. 2007;81(1):61-5.
  • Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leukemia & Lymphoma. 2006;47(8):1535-44.
  • Chang, S, Long SR, Kutikova L, Bowman L, Crown WH, Lyman GH. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology. 2006;70(1):71-80.
  • Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. Journal of Managed Care Pharmacy. 2006;12(1):43-54.
  • Kinchen KS, Long S, Chang S, Girts TK, Pantos B. The direct cost of stress urinary incontinence among women in a Medicaid population. American Journal of Obstetrics & Gynecology. 2005;193(6):1936-44.
  • Kutikova L, Bowman L, Chang S, Long SR, Obasajua C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143–54.
  • Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. Journal of Clinical Oncology. 2004;22(17):3524-30.
  • Ozminkowski RJ, Goetzel RZ, Chang S, Long S. The application of two health and productivity instruments at a large employer. Journal of Occupational and Environmental Medicine. 2004;46(7):635-48.
  • Crystal-Peters J, Chang S, Long S, Tertiak R. Healthcare expenditures of patients with major depressive disorder and post-traumatic stress disorder. European Psychiatry. 2002;17 Suppl 1:150.
  • Wysocki AB, Kusakabe A, Chang S, Tuan TL. Temporal expression of uPA and PAI-1 and MMP-9 in chronic wound fluid switches from a chronic to acute profile with progression to healing. Wound Repair Regeneration. 1999;7:154-65.
  • Chang S, Risch HA. Perineal talc exposure and risk of ovarian carcinoma. Cancer. 1997;79:2396-401.
  • Tuan TL, Song A, Chang S, Younai S, Nimni ME. In vitro fibroplasia: matrix contraction, cell growth, and collagen production of fibroblasts cultured in fibrin gels. Experimental Cell Research. 1996;223(1):127-34.

Presentations by this expert

  • Chang S. Analytic tools for medical and drug claims analysis: an example with treatment pathways. e-Health Initiative 2012 Forum on Data and Analytics; August 9, 2012.
  • Chang S. Treatment pathways. Institute of Medicine, Health Data Initiative Forum; June 9, 2011.
  • Marder WD, Chang S, Pepitone T, Hatzmann H, Mark T, Goodrich K. US government initiatives for supporting comparative effectiveness research, an example from Project Libra. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Meeting; November 6–9, 2011.
  • Danielson D, Chang S, Long S. Linking claims and electronic medical record (EMR) data for a hypertension study. ISPOR Annual International Meeting; May 16–19, 2010.
  • Misra A, Hansen L, Chang S. Drug-drug interactions among elderly patients with diabetes. International Conference of Pharmacoepidemiology (ICPE) Annual Conference; August 16–19, 2009.
  • Mark T, Chang S. Outpatient continuation of inpatient antipsychotic prescriptions: a linked data analysis. ICPE Annual Conference; August 16–19, 2009.
  • Curkendall S, Hansen L, Chang S, Mark T. Projected exposure to drugs on FDA's watch list. ICPE Annual Conference; August 16–19, 2009.
  • Foley K, Chang S, Misra A, Hansen L. Monitoring potential drug-drug interactions: an application for prescription claims databases. ISPOR Annual European Congress, Athens, Greece; November 8–11, 2008.
  • Hansen L, Chang S, Foley K. Prevalence of conditions in the US employer-insured population. ISPOR Annual International Meeting, Toronto, Canada; May 3–7, 2008.
  • Chang S, Huse D, Hansen L. Measuring the effect of an inpatient stay on adherence to medications: clopidogrel bisulfate use post-discharge. Pharmaceutical Management Science Association (PMSA) Annual Conference, Las Vegas, NV; April 26–30, 2008.
  • Chang S, Hansen L, Marder WD. Projecting diabetes prevalence and treatment rates to the US employer-insured population. ICPE Annual Conference, Quebec City, Quebec; August 22, 2007.
  • Chang S, Hansen LG, Marder WD. A methodology for projecting disease prevalence, treatment, and expenditures for the US employer-insured population. ISPOR Annual International Meeting, Arlington, VA; May 20, 2007.
  • Long S, Robinson R, Chang S. Variations in depression treatment quality: Medicaid versus commercial claims. Academy Health Annual Research Meeting, Boston, MA; June 26–28, 2005.
  • Chang S, Mark TL, Brandenburg N. Economic burden of generalized anxiety disorder (GAD) and other anxiety disorders. ISPOR Annual International Meeting, Washington, DC; May 15–18, 2005.
  • Long S, Robinson R, Chang S, Able S, Baser O, Swindle R. Appropriateness and variation in drug utilization across patients with depression. ISPOR Annual International Meeting, Washington, DC; May 15–18, 2005.
  • Kinchen K, Chang S, Girts TK, Long S, Pantos B. The direct costs of stress urinary incontinence treatment among women in a Medicaid population. ISPOR Annual International Meeting, Washington, DC; May 15–18, 2005.
  • Chang S, Long S, Kutikova L, Bowman L, Crown WH. Economic burden of pancreatic cancer and treatment failure. ISPOR Annual International Meeting, Arlington, VA; May 16–19, 2004.
  • Ozminkowski RJ, Goetzel RZ, Chang S, Long S, Lerner D. The application of two health and productivity instruments at a large employer. ISPOR Annual International Meeting, Arlington, VA; May 16–19, 2004.
  • Chang S, Long S, Leahy M, Crown WH. Healthcare expenditures of patients with comorbid allergic rhinitis and asthma. ISPOR Annual International Meeting, Arlington, VA; May 16–19, 2004.
  • Chang S, Kutikova K, Bowman L, Long S. Treatment costs and utilization of healthcare services by colorectal and pancreatic cancer patients. American Society of Clinical Oncology (ASCO), Chicago, IL; May 31–June 3, 2003.
  • Kutikova L, Bowman L, Chang S, Long S. Cost of cancer to healthcare: costs by treatment course and costs associated with failed treatment of patients with seven tumor types. ASCO, Chicago, IL; May 31–June 3, 2003.
  • Bowman L, Kutikova L, Chang S, Long S. Utilization of healthcare services and treatment costs in men with prostate cancer compared to men without cancer. ASCO, Chicago, IL; May 31–June 3, 2003.
  • Chang S, Orsini LS, Long S, Crown W. Prevalence rate and cost of depression among prostate cancer patients. ISPOR Annual Meeting, Arlington, VA; May 20–22, 2003.
  • Crystal-Peters J, Chang S, Long S, Tertiak R. Healthcare expenditures of patients with major depressive disorder and post-traumatic stress disorder. ISPOR Annual Meeting, Arlington, VA; May 20–22, 2002.
  • Crystal-Peters J, Chang S, Tertiak R. Healthcare expenditures of patients with major depressive disorder and post-traumatic stress disorder. Academy of Managed Care Pharmacy Annual Meeting, Salt Lake City, UT; April 3–6, 2002.
  • Chang S, Kennedy S, Tertiak R, Grudzinski A. Drug use patterns and relapse rates for patients on selective serotonin reuptake inhibitors (SSRIs). American Psychiatric Association Annual Meeting, Philadelphia, PA; May 20–22, 2002.
Contact 1
Hi! Looking to learn more about Veradigm?
Contact

Hello! Which of these are you interested in?

Which Biopharma and Device products are you interested in?

Which Health Plans and Payers products are you interested in?

Which Healthcare Providers products are you interested in?

Which Health IT Partners products are you interested in?

It looks like you're interested in Stella Chang. Please provide some final details:

--
1 of 5